Europe Neuromodulation Devices Market by Procedure [Internal Stimulation (DBS, GES, SNS, SCS, VNS), and External Stimulation (TENS, TMS)], and by Geography – Analysis & Forecast to 2019
This report covers definition, description, and forecasts for the European neuromodulation market. It involves a detailed analysis of the market segmentation, which comprises procedure and modality. The report also provides the strategic analysis of the key players in this market. Based on procedure types, the European neuromodulation market is segmented into internal stimulation and external stimulation, wherein the internal stimulation segment dominates the market registering an 85.9% in 2014. Based on modality, the neuromodulation market is categorized into spinal cord stimulation, deep brain stimulation vagus nerve stimulation, sacral nerve stimulation, gastric electric stimulation, transcutaneous electrical nerve stimulation (TENS), and transcranial magnetic stimulation (TMS).
The report also provides a detailed competitive landscaping of companies operating in this market. Segment- and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of major companies are detailed in the report. Boston Scientific (U.S.), Cyberonics (U.S), Medtronic, Inc. (U.S.), Depuy Synthes (Johnson & Johnson) (U.S.), and St. Jude Medical Inc. (U.S.) are some of the key players engaged in this market.
Amongst one of the advanced technologies, neuromodulation treats a wide range of chronic and refractory disorders. The minimally invasive and noninvasive nature of this technique increases its adoptability and hence is considered as an outpatient procedure. Moreover, these therapies are reversible, that is, non-destructive, which allow physicians to cease treatment as and when required by removing the stimulating devices.
Growing prevalence of lower urinary tract diseases is creating growth opportunities for the neuromodulation market. According to a study by the British Journal of Urology International (BJUI), it was estimated that, by 2018, 2.3 billion individuals will be affected by at least one type of lower urinary tract symptoms (LUTS) such as overactive bladder (OAB) and urinary incontinence (UI). Globally, a rise of 18% to 19% is expected in the incidence of LUTS disorders. However, complex reimbursement structure across the globe, cost of devices, lack of trained professionals to carry out these procedures, and presence of alternate therapies like drugs and electroconvulsive therapy will hamper the growth of this market.
Table of Contents
1 Introduction (Page No. - 11)
1.1 Objectives of the Study
1.2 Market Segmentation & Coverage
1.3 Stakeholders
2 Research Methodology (Page No. - 13)
2.1 Integrated Ecosystem of Neuromodulation Market
2.2 Arriving at the Europe Neuromodulation Market Size
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.2.3 Macroindicator-Based Approach
2.3 Assumptions
3 Executive Summary (Page No. - 20)
4 Market Overview (Page No. - 22)
4.1 Introduction
4.2 Neuromodulation Market: Comparison With Parent Market (Nerve Repair & Regeneration), 2013–2019 (USD MN)
4.3 Market Drivers and Inhibitors
4.4 Key Market Dynamics
5 Europe Neuromodulation Market, By Procedure (Page No. - 27)
5.1 Introduction
5.2 Europe Internal Stimulation
5.2.1 Europe Neuromodulation Market For Spinal Cord Stimulation, By Geography
5.2.2 Europe Neuromodulation Market For Deep Brain Stimulation, By Geography
5.2.3 Europe Neuromodulation Market For Vagus Nerve Stimulation, By Geography
5.2.4 Europe Neuromodulation Market For Sacral Nerve Stimulation, By Geography
5.2.5 Europe Neuromodulation Market For Gastric Electrical Stimulation, By Geography
5.3 Europe External Stimulation
5.3.1 Europe Neuromodulation Market For Transcutaneous Electrical Nerve Stimulation, By Geography
5.3.2 Europe Neuromodulation Market For Transcranial Magnetic Stimulation, By Geography
6 Europe Neuromodulation Market, By Geography (Page No. - 39)
6.1 Introduction
6.2 Germany Neuromodulation Market, By Procedure
6.2.1 Germany Neuromodulation Market, By Internal Stimulation
6.2.2 Germany Neuromodulation Market, By External Stimulation
6.3 France Neuromodulation Market, By Procedure
6.3.1 France Neuromodulation Market, By Internal Stimulation
6.3.2 France Neuromodulation Market, By External Stimulation
6.4 U.K. Neuromodulation Market, By Procedure
6.4.1 U.K. Neuromodulation Market, By Internal Stimulation
6.4.2 U.K. Neuromodulation Market, By External Stimulation
6.5 Italy Neuromodulation Market, By Procedure
6.5.1 Italy Neuromodulation Market, By Internal Stimulation
6.5.2 Italy Neuromodulation Market, By External Stimulation
6.6 Spain Neuromodulation Market, By Procedure
6.6.1 Spain Neuromodulation Market, By Internal Stimulation
6.6.2 Spain Neuromodulation Market, By External Stimulation
7 Europe Neuromodulation Market: Competitive Landscape (Page No. - 64)
7.1 Europe Neuromodulation Market: Market Share Analysis
7.2 Company Presence in European Neuromodulation Market, By Type
7.1 Mergers & Acquisitions
7.2 Expansions
7.3 Investments
7.4 Joint Ventures
7.5 Product Approvals
7.6 New Product Developement
8 Europe Neuromodulation Market: By Company (Page No. - 71)
(Overview, Financials, Products & Services, Strategy, and Developments)*
8.1 Boston Scientific Corporation
8.2 Cerbomed GmbH
8.3 Cyberonics, Inc.
8.4 Depuy Synthes
8.5 Medtronic, Inc.
8.6 St. Jude Medical
8.7 Uroplasty, Inc.
8.8 ANM Adaptive Neuromodulation GmbH
8.9 The Magstim Company Limited
8.1 Biocontrol Medical, Ltd.
*Details on Overview, Financials, Product & Services, Strategy, and Developments Might Not Be Captured in Case of Unlisted Company
9 Appendix (Page No. - 93)
9.1 Customization Options
9.1.1 Product Analysis
9.1.2 Epidemiology Data
9.1.3 Procedure Volume Data
9.1.4 Surgeon/Physician Perception Analysis
9.1.5 Brand/Product Perception Matrix
9.1.6 Pricing Trends
9.1.7 Competitive Intelligence
9.2 Related Reports
9.3 Introducing RT: Real Time Market Intelligence
9.3.1 RT Snapshots
List of Tables (50 Tables)
Table 1 Europe Neuromoldulation Market: Macroindicators,By Country, 2014 (USD MN)
Table 2 Europe Neuromodulation Market: Comparison With Parent Market (Nerve Repair & Regeneration), 2013 – 2019 (USD Million)
Table 3 Europe Neuromodulation Market: Drivers and Inhibitors
Table 4 Europe: Neuromodulation Market, By Procedure, 2013 – 2019 (USD MN)
Table 5 Europe: Neuromodulation Market, By Internal Stimulation, 2013 – 2019 (USD MN)
Table 6 Europe: Neuromodulation Market, By External Stimulation, 2013 – 2019 (USD MN)
Table 7 Europe: Neuromodulation Market, By Geography, 2013 - 2019 (USD MN)
Table 8 Europe: Neuromodulation Market, By Procedure, 2013 – 2019 (USD MN)
Table 9 Europe: Neuromodulation Market, By Internal Stimulation, 2013 - 2019 (USD MN)
Table 10 Europe: Neuromodulation Market For Spinal Cord Stimulation, By Geography, 2013 - 2019 (USD MN)
Table 11 Europe: Neuromodulation Market For Deep Brain Stimulation, By Geography, 2013 - 2019 (USD MN)
Table 12 Europe: Neuromodulation Market For Vagus Nerve Stimulation, By Geography, 2013 - 2019 (USD MN)
Table 13 Europe: Neuromodulation Market For Sacral Nerve Stimulation By Geography, 2013 - 2019 (USD MN)
Table 14 Europe: Neuromodulation Market For Gastric Electrical Stimulation, By Geography, 2013 - 2019 (USD MN)
Table 15 Europe: Neuromodulation Market, By External Stimulation, 2013 - 2019 (USD MN)
Table 16 Europe: Neuromodulation Market For Transcutaneous Electrical Nerve Stimulation, By Geography, 2013 - 2019 (USD MN)
Table 17 Europe: Neuromodulation Market For Transcranial Magnetic Stimulation, By Geography, 2013 - 2019 (USD MN)
Table 18 Europe: Neuromodulation Market, By Geography, 2013 - 2019 (USD MN)
Table 19 Germany: Neuromodulation Market, By Procedure, 2013 - 2019 (USD MN)
Table 20 Germany: Neuromodulation Market, By Internal Stimulation, 2013 - 2019 (USD MN)
Table 21 Germany: Neuromodulation Market, By External Stimulation, 2013 - 2019 (USD MN)
Table 22 France: Neuromodulation Market, By Procedure, 2013 - 2019 (USD MN)
Table 23 France: Neuromodulation Market, By Internal Stimulation, 2013 - 2019 (USD MN)
Table 24 France: Neuromodulation Market, By External Stimulation, 2013 - 2019 (USD MN)
Table 25 U.K.: Neuromodulation Market, By Procedure, 2013 - 2019 (USD MN)
Table 26 U.K.: Neuromodulation Market, By Internal Stimulation, 2013 - 2019 (USD MN)
Table 27 U.K.: Neuromodulation Market, By External Stimulation, 2013 - 2019 (USD MN)
Table 28 Italy: Neuromodulation Market, By Procedure, 2013 - 2019 (USD MN)
Table 29 Italy: Neuromodulation Market, By Internal Stimulation, 2013 - 2019 (USD MN)
Table 30 Italy: Neuromodulation Market, By External Stimulation, 2013 - 2019 (USD MN)
Table 31 Spain Neuromodulation Market, By Procedure, 2013 - 2019 (USD MN)
Table 32 Spain: Neuromodulation Market, By Internal Stimulation, 2013-2019 (USD MN)
Table 33 Spain: Neuromodulation Market, By External Stimulation, 2013 - 2019 (USD MN)
Table 34 Europe Neuromodulation Market: Market Share Analysis, 2013 (%)
Table 35 Europe Neuromodulation Market: Mergers & Acquisitions
Table 36 Europe Neuromodulation Market: Expansions
Table 37 Europe Neuromodulation Market: Investments
Table 38 Europe Neuromodulation Market: Agreement
Table 39 Europe Neuromodulation Market: Product Approvals
Table 40 Europe Neuromodulation Market: New Product Development
Table 41 Boston Scientific Corporation: Key Financials, By Segment, 2009 - 2013 (USD MN)
Table 42 Boston Scientific Corporation: Key Financials, By Region, 2009 - 2012 (USD MN)
Table 43 Cyberonics, Inc.: Key Financials, 2009 - 2013 (USD MN)
Table 44 Johnson & Johnson, Inc.: Key Financials, By Segment, 2009 - 2013 (USD MN)
Table 45 Johnson & Johnson, Inc.: Key Financials, By Region, 2009 – 2013 (USD MN)
Table 46 Medtronic, Inc.: Key Financials, By Segment, 2009 - 2013 (USD MN)
Table 47 Medtronic, Inc.: Key Financials, By Region, 2009 - 2013 (USD MN)
Table 48 St. Jude Medical: Key Financials, By Segment, 2011 - 2013 (USD MN)
Table 49 St. Jude Medical: Key Financials, By Region, 2009 - 2013 (USD MN)
Table 50 Uroplasty, Inc.: Key Financials, By Region, 2011 - 2013 (USD MN)
List of Figures (56 Figures)
Figure 1 European Neuromodulation Market: Segmentation & Coverage
Figure 2 Neuromodulation Market: Integrated Ecosystem
Figure 3 Research Methodology
Figure 4 Top-Down Approach
Figure 5 Bottom-Up Approach
Figure 6 Macroindicator-Based Approach
Figure 7 Europe Neuromodulation Market Snapshot (Top Markets), 2014
Figure 8 Europe Neuromodulation Procedures Market, By Geography, 2014 (USD MN)
Figure 9 Europe Neuromodulation Market, By Procedure, 2014 vs 2019 (USD MN)
Figure 10 Europe Neuromodulation Market, By Procedure, 2013 – 2019 (USD MN)
Figure 11 Europe Neuromodulation Market, By Internal Stimulation, 2014 vs 2019 (USD MN)
Figure 12 Europe Neuromodulation Market For Spinal Cord Stimulation, By Geography, 2014 - 2019 (USD MN)
Figure 13 Europe Neuromodulation Market For Deep Brain Stimulation, By Geography, 2014 - 2019 (USD MN)
Figure 14 Europe Neuromodulation Market For Vagus Nerve Stimulation, By Geography, 2013 - 2019 (USD MN)
Figure 15 Europe Neuromodulation Market For Sacral Nerve Stimulation, By Geography, 2013 - 2019 (USD MN)
Figure 16 Europe Neuromodulation Market For Gastric Electrical Stimulation, By Geography, 2013 - 2019 (USD MN)
Figure 17 Europe Neuromodulation Market, By External Stimulation, 2014 vs 2019 (USD MN)
Figure 18 Europe Neuromodulation Market For Transcutaneous Electrical Nerve Stimulation, By Geography, 2014 - 2019 (USD MN)
Figure 19 European Neuromodulation Market For Transcranial Magnetic Stimulation, By Geography, 2013 - 2019 (USD MN)
Figure 20 Europe Neuromodulation Market: Growth Analysis, By Geography, 2014 (USD Million)
Figure 21 Germany Neuromodulation Market, By Procedure, 2014 - 2019 (USD MN)
Figure 22 Germany Neuromodulation Market: Procedure Snapshot
Figure 23 Germany Neuromodulation Market, By Internal Stimulation, 2014 – 2019 (USD MN)
Figure 24 Germany Internal Neuromodulation Market: Snapshot
Figure 25 Germany Neuromodulation Market, By External Stimulation, 2014 – 2019 (USD MN)
Figure 26 Germany External Neuromodulation Market: Snapshot
Figure 27 France Neuromodulation Market, By Procedure, 2014 - 2019 (USD MN)
Figure 28 France Neuromodulation Market: Procedure Snapshot
Figure 29 France Neuromodulation Market, By Internal Stimulation, 2014–2019 (USD MN)
Figure 30 France Internal Neuromodulation Market: Snapshot
Figure 31 France Neuromodulation Market, By External Stimulation, 2014 – 2019 (USD MN)
Figure 32 France External Neuromodulation Market: Snapshot
Figure 33 U.K. Neuromodulation Market, By Procedure, 2014 - 2019 (USD MN)
Figure 34 U.K. Neuromodulation Market: Procedure Snapshot
Figure 35 U.K. Neuromodulation Market, By Internal Stimulation, 2014 – 2019 (USD MN)
Figure 36 U.K. Internal Neuromodulation Market: Snapshot
Figure 37 U.K. Neuromodulation Market, By External Stimulation, 2014–2019 (USD MN)
Figure 38 U.K. External Neuromodulation Market: Snapshot
Figure 39 Italy Neuromodulation Market, By Procedure, 2014 - 2019 (USD MN)
Figure 40 Italy Neuromodulation Market: Procedure Snapshot
Figure 41 Italy Neuromodulation Market, By Internal Stimulation, 2014 – 2019 (USD MN)
Figure 42 Italy Internal Neuromodulation Market: Snapshot
Figure 43 Italy Neuromodulation Market, By External Stimulation, 2014 – 2019 (USD MN)
Figure 44 Italy External Neuromodulation Market: Snapshot
Figure 45 Spain Neuromodulation Market, By Procedure, 2014 - 2019 (USD MN)
Figure 46 Spain Neuromodulation Market: Procedure Snapshot
Figure 47 Spain Neuromodulation Market, By Internal Stimulation, 2014 – 2019 (USD MN)
Figure 48 Spain Internal Neuromodulation Market: Snapshot
Figure 49 Spain Neuromodulation Market, By External Stimulation, 2014 – 2019 (USD MN)
Figure 50 Spain External Neuromodulation Market: Snapshot
Figure 51 Europe Neuromodulation Market Share Analysis, 2013 (%)
Figure 52 Europe Neuromodulation Market: Company Product Coverage, By Type, 2013
Figure 53 Boston Scientific Corporation: Business Revenue Mix, 2013
Figure 54 Depuy Synthes: Revenue Mix, 2013
Figure 55 Medtronic, Inc.: Revenue Mix, 2013
Figure 56 St. Jude Medical.: Revenue Mix, 2013
Neuromodulation treats a wide range of chronic and refractory disorders. The minimally invasive and noninvasive nature of this technique increases its adoptability and hence is considered as an outpatient procedure. Moreover, these therapies are reversible, that is, non-destructive. This allows physicians to cease treatment as and when required by removing the stimulating devices.
The European neuromodulation market was valued at $1,223.5 million in 2014 and is estimated to reach $2,310.6 million by 2019, at a CAGR of 13.6% between 2014 and 2019. Based on procedure, the market is segmented into internal neurostimulation and external neurostimulation, wherein the internal neurostimulation segment dominates the market and is estimated to reach $2,001.5 million by 2019.
Based on internal stimulation, the market is categorized into spinal cord stimulation, deep brain stimulation vagus nerve stimulation, sacral nerve stimulation, and gastric electric stimulation. Among these, the spinal cord stimulation segment leads the market and is projected to reach $1,134.6 million by 2019. The external stimulation modality is categorized into transcutaneous electrical nerve stimulation (TENS) and transcranial magnetic stimulation (TMS); the TENS segment leads the market and is projected to reach $232.9 million by 2019.
Growing prevalence of lower urinary tract diseases is creating growth opportunities for the neuromodulation market. According to a study by the British Journal of Urology International (BJUI), it was estimated that, by 2018, 2.3 billion individuals will be affected by at least one type of lower urinary tract symptoms (LUTS) such as overactive bladder (OAB) and urinary incontinence (UI). Globally, a rise of 18% to 19% is expected in the incidence of LUTS disorders.
However, complex reimbursement structure across the globe, cost of devices, lack of trained professionals to carry out these procedures, and availability of drugs and alternate therapies such as electroconvulsive therapy are expected to hamper market growth.
The major players in the neuromodulation market include Boston Scientific (U.S.), Cyberonics (U.S), Medtronic, Inc. (U.S.), Johnson & Johnson (U.S.), and St. Jude Medical Inc. (U.S.).
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
PRODUCT TITLE | PUBLISHED | |
---|---|---|
North American Nerve Repair & Regeneration Market The North American Nerve Repair and Regeneration market was pegged at $2841.03 million in 2013 and expected to be $4709.59 million by 2018, growing at a CAGR of 10.6%. Nerve Repair and Regeneration market segment includes direct nerve repair, nerve grafting, and stem cell therapy, while the neuromodulation segment includes internal stimulation devices such as Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES), and external stimulation devices such as Transcranial Magnetic Stimulation (TMS) and Transcutaneous Electrical Nerve Stimulation (TENS). The main companies operating The North American Nerve Repair and Regeneration market segment include Integra LifeSciences Corporation (U.S.), Stryker Corporation (U.S.), AxoGen, Inc. (U.S.), and Polyganics (The Netherlands). The key players in the neuromodulation segment include Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corp. (U.S.), St. Jude Medical, Inc. (U.S.), Enteromedics, Inc. (U.S.), Dynatronics Corp. (U.S.), and Neuronetics (U.S.). |
Apr 2015 | |
European Nerve Repair & Regeneration Market The nerve repair and regeneration market in Europe has displayed significant growth at a CAGR of 11.9%. Germany garnered the maximum market share and is expected to grow at a CAGR of 11.1%, followed by France and the U.K. |
Apr 2015 | |
Asian Nerve Repair & Regeneration Market The Asian Nerve Repair and Regeneration market was pegged at $4680.82 million in 2013 and expected to be $8112.19 million by 2018, growing at a CAGR of 11.6%. market segment includes direct nerve repair, nerve grafting, and stem cell therapy, while the neuromodulation segment includes internal stimulation devices such as Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES), and external stimulation devices such as Transcranial Magnetic Stimulation (TMS) and Transcutaneous Electrical Nerve Stimulation (TENS). The main companies operating in peripheral nerve repair segment include Integra LifeSciences Corporation (U.S.), Stryker Corporation (U.S.), AxoGen, Inc. (U.S.), and Polyganics (The Netherlands). The key players in the neuromodulation segment include Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corp. (U.S.), St. Jude Medical, Inc. (U.S.), Enteromedics, Inc. (U.S.), Dynatronics Corp. (U.S.), and Neuronetics (U.S.). |
Mar 2015 |